The London RMOC Polypharmacy Subgroup should use this summary and additional evidence they are aware of to achieve the following actions requested by the London RMOC:
Identify how medication reviews to address polypharmacy could be delivered
Suggest a delivery model and identify barriers / enablers to achieve this
This will be achieved at the meeting through discussing the following:
1. Role of different professions in medicines optimisation review 2. What medicines optimisation review looks like in primary care 3. What medicines optimisation review looks like in secondary care 4. How a programme will be evaluated and measured
Page 27 of 29
References
[1] N. Jokanovic, E. Tan, S. Sudhakaran, C. Kirkpatrick, M. Dooley, T. Ryan‐Atwood and S. Bell, “Pharmacist‐led medication review in community settings: An overview of systematic reviews,” Research in Social and Administrative Pharmacy, vol. 13, pp. 661 ‐ 685, 2017.
[2] N. Masnoon, S. Shakib, L. Kalisch‐Ellett and G. Caughey, “What is polypharmacy? A systematic review of definitions,” BMC Geriatrics, vol. 17, p. 230, 2017.
[3] National Institute for Health and Care Excellence, “KTT18: Multimorbidity and polypharmacy. Options for local implementation.,”
NICE, 02 2018. [Online]. Available: https://www.nice.org.uk/advice/ktt18/chapter/Options‐for‐local‐implementation. [Accessed 22 05 2018].
[4] M. Duerden, T. Avery and R. Payne, “Polypharmacy and medicines optimisation: Making it safe and sound,” The King's Fund, London, 2013.
[5] NHS England, “Medicines Optimisation,” [Online]. Available: https://www.england.nhs.uk/medicines/medicines‐optimisation/.
[Accessed 22 08 2019].
[6] L. Donaldson, E. Kelley, N. Dhingra‐Kumar, M.‐P. Kieny and A. Sheikh, “Medication Without Harm: WHO's Third Global Patient Safety Challenge,” Lancet, vol. 389, pp. 1680 ‐ 1681, 2017.
[7] R. Elliott, E. Camacho, F. Campbell, D. Jankovic, M. Martyn St James, E. Kaltenthaler, R. Wong, M. Sculpher and R. Faria, “EEPRU:
Prevalence and economic burden of medication errors in the NHS in England,” 22 02 2018. [Online]. Available:
http://www.eepru.org.uk/wp‐content/uploads/2018/02/eepru‐report‐medication‐error‐feb‐2018.pdf. [Accessed 15 05 2018].
[8] K. Viktil, H. Blix, T. Moger and A. Reikvam, “Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug‐related problems.,” Br J Clin Pharmacol, vol. 63, no. 2, pp. 187 ‐ 195, 2007.
[9] N. Parekh, K. Ali, J. Stevenson, J. Davies, R. Schiff, T. Van der Cammen, J. Harchowal, J. Raftery and C. Rajkumar, “Incidence and cost of medication harm in older adults following hospital discharge: A multicentre prospective study in the UK,” Br J Clin Pharmacol, p. doi:
10.1111/bcp.13613, 2018.
[10] E. Baker, Personal communication: Pathways to polypharmacy, 2018.
[11] E. Baker, Personal communication: Prevention and treatment of polypharmacy, 2018.
[12] Z. Loh, M. Cheen and H. Wee, “Humanistic and economic outcomes of pharmacist‐provided medication review in the community‐
dwelling elderly: A systematic review and meta‐analysis,” Journal of Clinical Pharmacy and Therapeutics, vol. 41, pp. 621 ‐ 633, 2016.
[13] M. Viswanathan, L. Kahwati, C. Golin, S. Blalock, E. Coker‐Schwimmer, R. Posey and K. Lohr, “Medication Therapy Management Interventions in Outpatient Settings: A systematic review and meta‐analysis,” JAMA Intern Med, vol. 175, no. 1, pp. 76 ‐ 87, 2015.
[14] N. Jokanovic, E. Tan, D. van den Bosch, C. Kirkpatrick, M. Dooley and J. Bell, “Clinical medication review in Australlia: A systematic review,” Research in Social and Administrative Pharmacy, vol. 12, pp. 384 ‐ 418, 2016.
[15] E. Tan, K. Stewart, R. Elliott and J. George, “Pharmacist services provided in general practice clinics: a systematic review and meta‐
analysis,” Research in Social and Administrative Pharmacy, vol. 10, pp. 608 ‐ 622, 2014.
[16] M. Christensen and A. Lundh, “Medication review in hospitalised patients to reduce morbidity and mortality,” Cochrane Database of Systematic Reviews, vol. 2, p. DOI: 10.1002/14651858.CD008986.pub3, 2016.
[17] S. Kallio, A. Kiiski, M. Airaksinen, A. Mantyla, A. Kumpusalo‐Vauhkonen, T. Jarvensivu and M. Pohjanoksa‐Mäntylä, “Community pharmacists' contribution to medication reviews for older adults: a systematic review,” J Am Geriatr Soc, vol. 66, no. 8, pp. 1613 ‐ 1620, 2018.
Page 28 of 29
[18] S. Wallerstedt, J. Kindblom, K. Nylen, O. Samuelsson and A. Strandell, “Medication reviews for nursing home residents to reduce mortality and hospitalization: systematic review and meta‐analysis,” Br J Clin Pharmacol, vol. 78, no. 3, pp. 488 ‐ 497, 2014.
[19] National Institute for Health and Care Excellence, “NICE Guideline 5: Medicines Optimisation ‐ The safe and effective use of medicines to enable the best possible outcomes [Full Guidelilne],” March 2015. [Online]. Available:
https://www.nice.org.uk/guidance/ng5/evidence/full‐guideline‐pdf‐6775454. [Accessed 23 06 2018].
[20] J. Beuscart, L. Pont, S. Thevelin, B. Boland, O. Dalleur, A. Rutjes, J. Westbrook and A. Spinewine, “A systematic review of the outcomes reported in trials of medication review in older patients: the need for a core outcome set,” Br J Clin Pharm, vol. 83, pp. 942 ‐ 952, 2017.
[21] J.‐B. Beuscart, W. Knol, S. Cullinan, C. Schneider, O. Dalleur, B. Boland, S. Thevelin, P. Jansen, D. O'Mahony, N. Rodondi and A.
Spinewine, “International core outcome set for clinical trials of medication review in multi‐morbid older patients with polypharmacy.,” BMC Medicine, vol. 16, no. 21, 2018.
[22] R. Holland, E. Lenaghan, I. Harvey, R. Smith, L. Shepstone, A. Lipp, M. Christou, D. Evans and C. Hand, “Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial,” BMJ, p. doi:10.1136/bmj.38338.674583.AE, 2005.
[23] C. Perraudin, O. Bugnon and N. Pelletier‐Fleury, “Expanding professional pharmacy services in European community setting: Is it cost‐
effective? A systematic review for health policy considerations,” Health Policy, vol. 120, no. 12, pp. 1350 ‐1362, 2017.
[24] S. Hasan, K. Thiruchelvam, C. Kow, M. Ghori and Z.‐U.‐D. Babar, “Economic evaluation of pharmacist‐led medication reviews in residential aged care facilities,” Expert Review of Pharmacoeconomics & Outcome Research, vol. 17, no. 5, pp. 431 ‐ 439, 2017.
[25] D. Sackett, W. Rosenberg, J. Gray, R. Haynes and W. Richardson, “Evidence based medicine: what it is and what it isn't,” BMJ, vol. 312, pp. 71‐72, 1996.
[26] R. Payne, Personal communication: Components of medication review, July 2019.
[27] H. Nazar, N. Brice, N. Akhter, A. Kasim, A. Gunning, S. Slight and N. Watson, “New transfer of care initiative of electronic referral from hospital to community pharmacy in England: a formative service evaluation.,” BMJ Open, vol. 6, p. e012532, 2016.
[28] C. Butterworth, Personal communication, 15/6/2018.
[29] Specialist Pharmacy Service, “A patient centred approach to polypharmacy,” 02 07 2015. [Online]. Available:
https://www.sps.nhs.uk/wp‐
content/uploads/2014/12/Patient20Centred20Approach20to20Polypharmacy20summary20formerly20seven20steps.pdf. [Accessed 15 05 2018].
[30] D. Garfinkle, “Poly‐de‐prescribing to treat polypharmacy: efficacy and safety,” Ther Adv Drug Saf, vol. 9, no. 1, pp. 25‐43, 2018.
[31] PwC, “Clinical Pharmacology and Therapeutics: The case for savings in the NHS,” PwC, London, 2016.
[32] E. Lenaghan, R. Holland and A. Brooks, “Home‐based medication review in a high risk elderly population in primary care ‐ the POLYMED randomised controlled trial.,” Age and Ageing, vol. 36, pp. 292 ‐ 297, 2007.
[33] N. Barnett, L. Oboh and K. Smith, “Patient‐centred management of polypharmacy: a process for practice.,” Eur J Hosp Pharm, vol. 23, no. 2, pp. 113 ‐ 117, 2016.
[34] Canadian Deprescribing Network, “Canadian Deprescribing Network,” [Online]. Available: https://deprescribing.org/caden/.
[Accessed 15 05 2018].
[35] Royal Pharmaceutical Society, “Foundation Pharmacy Framework,” RPS, 01 01 2014. [Online]. Available:
https://www.rpharms.com/resources/frameworks/foundation‐pharmacy‐framework‐fpf. [Accessed 07 06 2018].
[36] E. Baker, Personal communication: Post‐qualification prescriber training, 2018.
Page 29 of 29
[37] A. Clegg, C. Bates, J. Young, R. Ryan, L. Nichols, E. Ann Teale, M. Mohammed, J. Parry and T. Marshall, “Development and validation of an electronic frailty index using routine primary care electronic health record data,” Age Ageing, vol. 45, no. 3, pp. 353 ‐ 360, 2016.
[38] P. Donnan, D. Dorward, B. Mutch and A. Morris, “Development and validation of a model for predicting emergency admissions over the next year (PEONY): a UK historical cohort study,” Arch Intern Med, vol. 168, no. 13, pp. 1416 ‐ 1422, 2008.
[39] A. Avery, S. Rodgers, J. Cantrill, S. Armstrong, K. Cresswell, M. Eden, R. Elliott, R. Howard, D. Kendrick, C. Morris, R. Prescott, G.
Swanwick, M. Franklin, K. Putman, M. Boyd and A. Sheikh, “A pharmacist‐led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost‐effectiveness analysis.,” The Lancet, vol. 379, pp. 1310 ‐ 1319, 2012.
[40] NHS Business Services Authority, “Medicines Optimisation: Polypharmacy Prescribing Comparators,” July 2017. [Online]. Available:
https://www.nhsbsa.nhs.uk/sites/default/files/2018‐02/PolyPharmacy%20Specification%20v1%200%20July%202017_0.pdf.
[Accessed 07 06 2018].
[41] S. Williams, J. Hayes and L. Brad, “Clinical pharmacists in general practice: a necessity not a luxury?,” Br J Gen Pract, vol. 68, no. 667, p. 85, 2018.
[42] Department of Health & Social Care, “The Community Pharmacy Contractual Framework for 2019/20 to 2023/24: Supporting delivery for the NHS Long Term Plan,” DHSC, London, 2019.
[43] Choosing Wisely UK, “Choosing Wisely UK,” [Online]. Available: https://www.choosingwisely.co.uk/about‐choosing‐wisely‐uk/.
[Accessed 26 09 2019].
[44] NHS Highland, “Medicines Review: Important Information for Patients and Carers,” NHS Highland, 2013. [Online]. Available:
http://www.polypharmacy.scot.nhs.uk/media/1020/polypharmacy‐patient‐information‐leaflet‐a4‐format.pdf. [Accessed 31 05 2018].
[45] Royal Pharmaceutical Society, “Making the most of your medicines,” [Online]. Available:
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Hub/Medicines%20optimisation/patients‐‐‐
making‐the‐most‐of‐medicines.pdf. [Accessed 26 09 2019].
[46] M. Rawle, M. Richards, D. Davis and D. Kuh, “The prevalence and determinants of polypharmacy at age 69: a British birth cohort study,” BMC Geriatrics, vol. 18, p. 118, 2018.
[47] H.‐F. Kwint, L. Bermingham, A. Faber, J. Gussekloo and M. Bouvy, “The relationship between the extent of collaboration of general practitioners and pharmacists and the implementation of recommendations arising from medication review,” Drugs Aging, vol. 30, pp. 91 ‐ 102, 2013.
[48] National Institute of Health and Care Excellence, “KTT18: Multimorbidity and polypharmacy. Evidence context.,” NICE, 02 2018.
[Online]. Available: https://www.nice.org.uk/advice/ktt18/chapter/Evidence‐context#polypharmacy. [Accessed 22 05 2018].
[49] National Institute for Health and Care Excellence, “NICE Guideline 5: Medicines optimisation,” NICE, Manchester, 2015.
[50] Z.‐U.‐D. Babar, R. Kousar, G. Murtaza, S. Azhar, S. Khan and L. Curley, “Randomized controlled trials covering pharmaceutical care and medicines management: A systematic review of literature,” Research in Social and Administrative Pharmacy, p.
http://dx.doi.org/10.1016/j.sapharm.2017.06.008, 2017.